retatrutide triple agonist weight loss trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body change at 80 weeks: ⬇️ Who Makes Retatrutide? Company Behind

This makes it one of the most broadly beneficial peptides studied in regenerative medicine

The body seldom takes a single path, so interactions are uncertain

Working with a clinician to draw up an individualized care plan is your best chance at finding relief, which may include hormonal therapy, nonhormonal medical treatments, botanicals and supplements, and lifestyle changes

In the United States today, roughly three in four adults in midlife are living with at least one chronic health condition

Klebanoff, Pengxiang Li, Judith A

Important Considerations Individual Variation: Response to these strategies varies based on genetics, current gut health, metabolic status, and lifestyle factors